medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2018, Number 1

<< Back Next >>

Rev Mex Med Transfus 2018; 11 (1)

Frequency of irregular antibodies and associated factors in patients with cardiac pathology

Mejía AB, Palomino MR, Linares RV, Jiménez GMC

Language: Spanish
References: 32
Page: 11-21
PDF size: 201.56 Kb.


ABSTRACT

Introduction: Cardiopathic patients frequently require transfusional aid. At the time of a blood transfusion the patient is exposed to numerous foreign antigens, these antigens are potentially immunogenic, promoting the development of antibodies in the receptor, alloimmunized. Objective: To know the frequency of irregular antibodies in the population of transfused patients at the High Specialty Medical Unit (in Spanish: UMAE), Cardiology Hospital (CH), National Medical Center Siglo XXI (NMC-SXXI), including the possible factors associated to the development of antibodies. Material and methods: Through a descriptive, cross-sectional study, applied to the transfused population of the UMAE-CH-NMC-SXXI from May 2011 to June 2018; the frequency of antibodies was analyzed, identifying the associated factors of their development. Statistical program SPSS was performed, using frequency statistics and association through χ2 test. Results: 59,649 transfusions were performed, from which 66 patients presented alloimmunization. Most of the identified antibodies were from the Rh-Hr System, finding a 28% of anti-E. Associated factors: female gender, pregnancy antecedent, rheumatic heart disease, diabetes mellitus and transfusional antecedents. Conclusions: Along with the transfusional background and pregnancy antecedent; others factors should be considered in the alloimmunization risk increment. Once involved systems are identifiedin the development of antibodies, we can provide phenotype blood to the patient for a safely transfusion, decreasingthe risk of the antibodies development and associated reactions to the transfusion.


REFERENCES

  1. García GJ, Vargas PM, Rodríguez VP, Ramírez PA, Rosón PC, Corte BJ. Aloinmunización en pacientes politransfundidos. Sangre, Trabajos de Hematología y Hemoterapia. 2004; 39 (6): 417-421.

  2. Coles SM, Kleins HG, and Holland PV. Alloinmunization in two multitransfused patient populations. Transfusion. 1981; 21 (3): 462-466.

  3. World Health Organization. World Health Organization. “Top ten causes of death”. 2008 [Accessed 16 November 2012].Available:http://www.who.int/mediacentre/factsheets/fs310/en/index.html.

  4. García AC. Fundamentos de Banco de Sangre. Medicina y Laboratorio. 2009; 15: 329-346.

  5. Giblett ER. Genetic research in a blood bank laboratory. The Philip Levine award lecture. Am J Clin Pathol. 1979; 71 (1): 1-9.

  6. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell alloimmunization following transfusion. Vox Sang. 1996; 71: 216-220.

  7. Zaman S, Chaurasia R, Chatterjee K, Thapliyal RM. Prevalence and specificity of rbc alloantibodies in indian patients attending a tertiary care hospital. Adv Hematol. 2014; 2014: 1-5.

  8. Yousuf R, Abdul Aziz S, Yusof N, Leong CF. Incidence of red cell alloantibody among the transfusion recipients of UniversitiKebangsaan Malaysia Medical Centre. Indian J Hematol Blood Transfus. 2013; 29 (2): 65-70.

  9. Caamaño J, Musante E, Contreras M, Ulloa H, Reyes C, Inaipil V et al. Frequency and specificity of red blood cell alloimmunization in chilean transfused patients. Transfus Med Hemother. 2015; 42 (1): 4-7.

  10. Simancas-Racines D, Osorio D, Martí-Carvajal AJ, Arevalo-Rodriguez I. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database Syst Rev. 2015; 12: CD009745.

  11. Yazer MH, Triulzi DJ. Detection of anti-D in D–recipients transfused with D+ redblood cells.Transfusion. 2007; 47: 2197-2201.

  12. Zalpuri S, Schonewille H, Middelburg R, van de Watering L, de Vooght K, Zimring J et al. Effect of storage of red blood cells on alloimmunization. Transfusion. 2013; 53 (11): 2795-800.

  13. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, van der Bom JG. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang. 2012; 102: 144-149.

  14. Zalpuri S, Middelburg RA, Schonewille H, de Vooght KM, le Cessie S. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion. 2014; 54 (2): 278-284.

  15. Ryder AB, Zimring JC, Hendrickson JE.Factors influencing RBC alloimmunization.Transfus Med Hemother. 2014; 41: 406-419.

  16. Verduin EP1, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. Transfus Med Rev. 2012; 26 (4): 342-53,353.e1-5.

  17. Verduin EP, Brand A, Middelburg RA, Schonewille H. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion. 2015; 55 (6 Pt 2): 1478-1485.

  18. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007; 47: 2066-2071.

  19. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999; 39: 763-771.

  20. Hussein E, Desooky N, Rihan A, Kamal A. Predictors of red cell alloimmunization in multitransfused Egyptian patients with β-thalassemia. Arch Pathol Lab Med. 2014; 138 (5): 684-688.

  21. Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood. 2012; 119 (6): 1566-1569.

  22. Schonewille H1, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006; 46 (2): 250-256.

  23. Körmöczi GF, Mayr WR. Responder individuality in red blood cell alloimmunization. Transfus Med Hemother. 2014; 41 (6): 446-451.

  24. Mallhi RS, Dimri U, Jayamanna DR, Philip J. Presence of Irregular Antibody (Anti-c) in a Multitransfused Cardiac Surgery Patient. Indian J Hematol Blood Transfus. 2015; 31 (3): 385-386.

  25. Yu Y, Wang Y, Sun XL, Ma CY, Zhang XJ, Guan XZ et al. Prevalence and specificity of red blood cell alloantibodies in patients from china during 1994-2013. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015; 23 (6): 1734-1741.

  26. Pahuja S, Gupta SK, Pujani M, Jain M. The prevalence of irregular erythrocyte antibodies among antenatal women in Delhi. Blood Transfus. 2011; 9: 388-393.

  27. Ngoma AM, Mutombo PB, Ikeda K, Nollet KE, Natukunda B, Ohto H. Red blood cell alloimmunization in transfused patients in sub-Saharan Africa: a systematic review and meta-analysis. TransfusApher Sci. 2015; 2016; 54 (2): 296-302.pii: S1473-0502(15)00178-0.

  28. Li H, Xu HM, Zhang Y, Cui JX. Analysis of patients’ irregular antibody screening and identification results before blood transfusion. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015; 23 (3): 861-865.

  29. Garraty G. Problems in pre-transfusion tests related to drugs and chemicals. Am J Med Technol. 1976; 42 (6): 209-219.

  30. AmeenR, Al-ShemmariS. Frequency of red blood cell alloantibody in Kuwaiti population. Med PrincPract. 2005; 14: 230-234.

  31. Lasky LC, Rose RR, Polesky HF. Incidence of antibody formation and positive direct antiglobulin tests in a multitransfused hemodialysis population. Transfusion. 1984; 24 (3): 198-200.

  32. Rodriguez-Moyado H, Quintanar-Garcia E, Mejia-Arregui MH. El Banco de Sangre y la medicina transfusional. México, DF: Médica Panamericana; 2004. p. 159-160.




2020     |     www.medigraphic.com